Clinical Trial Update: Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or Macroadenomas [Phase 4]

View source ↗

Summary

A Phase 4 study evaluating octreotide acetate for acromegaly with micro or macroadenomas was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acromegaly

Drugs mentioned

• Sandostatin (Octreotide acetate)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Acromegaly | Phase 4 | Status: TERMINATED